Illinois-based Eton Pharmaceuticals is making its Alkindi Sprinkle hydrocortisone product available through a sole specialty distributor “to ensure that patients…receive appropriate drug and clinical counseling and to support therapeutic adherence,” the company informed 340B covered entities in a Jan. 12 notice on the U.S. Health Resources and Services Administration (HRSA) website.
Eton says in the notice that covered entities wishing to buy Alkindi Sprinkle should contact the exclusive distributor, AnovoRx Group, LLC, to serve as a contract pharmacy and to dispense the medicine directly to patients. The drug is for pediatric patients with adrenal insufficiency. It is an orphan drug and thus unavailable at 340B pricing to free-standing cancer hospitals, critical access hospitals, sole community hospitals, and rural referral centers, Eton said.
Illinois-based Eton Pharmaceuticals is making its Alkindi Sprinkle hydrocortisone product available through a sole specialty distributor “to ensure that patients…receive appropriate drug and clinical counseling and to support therapeutic adherence,” the company informed 340B covered entities in a Jan. 12 notice on the U.S. Health Resources and Services Administration (HRSA) website.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
